---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012611"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:14:26.057217+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# RxSight receives FDA request for additional info on lower-cost LDD; expects no timeline impact

## Summary
- FDA requested additional information for approval of lower-cost-to-manufacture Light Delivery Device (LDD).
- Commercial sale of the lower-cost LDD not planned until 2023; company believes it can meet the timeline.
- Lower-cost LDD has the same functionality as the currently marketed LDD.

## SEC filing metadata
- accession: 0000950170-22-012611
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/0000950170-22-012611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/rxst-20220711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012611
- JSON: https://secwatch.observer/filing/0000950170-22-012611.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.